Entrada Therapeutics (TRDA) presented at the first day of the 12th Annual Cantor Fitzgerald Global Healthcare Conference on Sept. 9, 2026. Analyst Yanni Souroutzidis and Entrada executives Nate Dowden and Natarajan Sethuraman discussed the company’s technology, financial position and clinical pipeline.
The company’s shares were trading at $7.17, down 4.65% from the prior close of $7.52, with a 52‑week high of $16.45. A later reference showed a close of $6.80 (+5.92%) and after‑hours at $6.48 (‑4.71%). Market capitalization stands at roughly $271 million. Analysts have set price targets between $11 and $25.
Entrada reported $223 million in cash, providing runway into the third quarter of 2027. The firm highlighted its partnership with Vertex Pharmaceuticals, which includes a $250 million upfront payment, up to $485 million in milestone fees and mid‑to‑high single‑digit royalties on future sales.
The core of Entrada’s platform is its Endosomal Escape Vehicle (EEV). Pre‑clinical data indicate that about 50% of administered material escapes the endosome, versus roughly 1% for conventional approaches. Conjugating therapeutic cargo to the EEV yields 25‑to‑50‑fold higher cytosolic delivery. Approximately 90% of the drug remains in the body one week after infusion, contrasting with rapid renal clearance of standard phosphorodiamidate morpholino oligomers (PMOs) of ~10,000 Da. In a healthy‑volunteer study at 6 mg/kg, kidney function markers and early proximal‑tubule biomarkers stayed within normal ranges.
Clinical pipeline updates were provided for three programs.
* ENTR‑601‑44, a wholly owned exon‑44 skipping candidate for Duchenne muscular dystrophy (DMD), completed Cohort 1 with a 6 mg/kg dose in a 6‑to‑2 design (six patients on therapy, two on placebo). Safety was clean, with eGFR, cystatin C and magnesium unchanged. Treated patients showed an average 6.3% dystrophin expression and an early functional gain in time‑to‑rise. Cohort 2 will test 12 mg/kg, and a potential Cohort 3 could reach 18 mg/kg pending data‑monitoring committee approval. An expansion cohort aims for a total safety database of about 40 patients to support an accelerated approval filing.
* ENTR‑601‑45, also wholly owned, targets exon 45 skipping for DMD, a more challenging exon. The company expects dosing every six weeks. Multiple‑ascending‑dose data for Cohort 1 are slated for Oct. 2024, focusing on safety. Cohort 2 will evaluate a 10 mg/kg dose, with Cohort 3 potentially reaching 15 mg/kg subject to committee sign‑off.
* VX‑670, developed with Vertex, targets myotonic dystrophy type 1 (DM1) using a CUG‑repeat steric‑block mechanism. Vertex holds commercial rights and leads development.
Entrada identified several near‑term data catalysts: ENTR‑601‑45 Cohort 1 readout in Oct. 2024; ENTR‑601‑44 open‑label extension data by year‑end 2024; ENTR‑601‑44 Cohort 2 data in Q1‑Q2 2025; and ENTR‑601‑45 Cohort 2 data in Q1‑Q2 2025.
The company’s cash position, partnership terms and upcoming trial milestones are intended to support continued development while the market evaluates the potential of the EEV platform to improve intracellular delivery of antisense therapeutics.
